Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) Equity Average (2016 - 2025)

Historic Equity Average for Ascendis Pharma A (ASND) over the last 4 years, with Q4 2022 value amounting to $362.0 million.

  • Ascendis Pharma A's Equity Average fell 6682.92% to $362.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $362.0 million, marking a year-over-year decrease of 6682.92%. This contributed to the annual value of -$135.6 million for FY2024, which is 34229.24% down from last year.
  • Ascendis Pharma A's Equity Average amounted to $362.0 million in Q4 2022, which was down 6682.92% from $551.9 million recorded in Q3 2022.
  • Ascendis Pharma A's Equity Average's 5-year high stood at $1.1 billion during Q4 2021, with a 5-year trough of $362.0 million in Q4 2022.
  • Over the past 3 years, Ascendis Pharma A's median Equity Average value was $890.6 million (recorded in 2021), while the average stood at $834.7 million.
  • Per our database at Business Quant, Ascendis Pharma A's Equity Average soared by 2214.53% in 2021 and then crashed by 6682.92% in 2022.
  • Over the past 3 years, Ascendis Pharma A's Equity Average (Quarter) stood at $1.1 billion in 2020, then grew by 3.36% to $1.1 billion in 2021, then tumbled by 66.83% to $362.0 million in 2022.
  • Its last three reported values are $362.0 million in Q4 2022, $551.9 million for Q3 2022, and $701.9 million during Q2 2022.